NASDAQ:LPTX

Leap Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy LPTX

*Your capital is at risk

$0.690

+0 (+0%)

At Close: Jun 23, 2026

LEAP THERAPEUTICS Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 93.31. In total, the insiders bought 2.89M and sold 68.6K LPTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	93.31
● Buy	2.89M shares
● Sell	68.6K shares
84% Buy Activity Moderate Negative Correlation
Sell Signal Low Confidence Jun 22, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 93.31. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Oct 02, 2024 Buy	Stock Option (Right to Buy) A-Award	Mirabelli Christopher Director	Director	85 000 Value: $208.3K
Oct 02, 2024 Buy	Stock Option (Right to Buy) A-Award	Cavanaugh James H Director	Director	25 000 Value: $61.3K
Oct 02, 2024 Buy	Stock Option (Right to Buy) A-Award	Dietz Thomas John Director	Director	30 000 Value: $73.5K
Oct 02, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Lawlor Augustine Chief Operating Officer	C-Suite Officer	85 000 Value: $208.3K
Oct 02, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	O'mahony John Mark Chief Manufacturing Officer	Officer	85 000 Value: $208.3K
Oct 02, 2024 Buy	Stock Option (Right to Buy) A-Award	Li William Director	Director	25 000 Value: $61.3K
Oct 02, 2024 Buy	Stock Option (Right to Buy) A-Award	Loscalzo Joseph Director	Director	25 000 Value: $61.3K
Oct 02, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Onsi Douglas E CEO,cfo,pres.,gc,treas.,&sec.	CEO / President	170 000 Value: $416.5K
Oct 02, 2024 Buy	Stock Option (Right to Buy) A-Award	Martin Patricia A. Director	Director	25 000 Value: $61.3K
Oct 02, 2024 Buy	Stock Option (Right to Buy) A-Award	Richard Christian M Director	Director	25 000 Value: $61.3K
Oct 02, 2024 Buy	Stock Option (Right to Buy) A-Award	Schilsky Richard Director	Director	25 000 Value: $61.3K
Oct 02, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Sirard Cynthia Chief Medical Officer	Officer	85 000 Value: $208.3K
Oct 02, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Granfield Christine Vp, Head Of Reg Affairs/qual	Officer	85 000 Value: $208.3K
Apr 10, 2024 Buy	Common Stock	Gilead Sciences, Inc. 10 Percent Owner	10% Owner	0 Value: $0
Apr 10, 2024 Buy	Common Stock	Gilead Sciences, Inc. 10 Percent Owner	10% Owner	0 Value: $0
Jan 29, 2024 Buy	Stock Option (Right to Buy) A-Award	Mashiach Nissim Director	Director	25 000 Value: $67.0K
Jan 29, 2024 Buy	Stock Option (Right to Buy) A-Award	Dietz Thomas John Director	Director	30 000 Value: $80.4K
Jan 29, 2024 Buy	Stock Option (Right to Buy) A-Award	Schilsky Richard Director	Director	25 000 Value: $67.0K
Jan 29, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Granfield Christine Vp, Head Of Reg Affairs/qual	Officer	85 000 Value: $227.8K
Jan 29, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Baum Jason Chief Scientific Officer	Officer	85 000 Value: $227.8K
Jan 29, 2024 Buy	Stock Option (Right to Buy) A-Award	Richard Christian M Director	Director	25 000 Value: $67.0K
Jan 29, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Granfield Christine Vp, Head Of Reg Affairs/qual	Officer	85 000 Value: $227.8K
Jan 29, 2024 Buy	Stock Option (Right to Buy) A-Award	Schilsky Richard Director	Director	25 000 Value: $67.0K
Jan 29, 2024 Buy	Stock Option (Right to Buy) A-Award	Dietz Thomas John Director	Director	30 000 Value: $80.4K
Jan 29, 2024 Buy	Stock Option (Right to Buy) A-Award	Mashiach Nissim Director	Director	25 000 Value: $67.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LEAP THERAPEUTICS INC.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and com...

Read Full Profile Here